Business Wire

IQM and TOYO Corporation Sign Distribution Agreement to Drive Quantum Adoption in Japan

6.8.2025 09:28:00 CEST | Business Wire | Press Release

Share

IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, and TOYO Corporation have signed a distribution agreement to accelerate quantum computing adoption for the Japanese market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806016289/en/

IQM and TOYO Corporation sign distribution agreement to drive quantum adoption in Japan

With the agreement, Toyo, which is a leading company in measurement technology and promoting technological innovation in Japan, will market and sell IQM Spark, a 5-qubit system, and IQM Radiance, which ranges from 20-qubit to 150-qubit on-premises superconducting quantum computers.

In addition, TOYO will also promote the cultivation of specialised talent in quantum technology and its societal implementation. Backed by significant government investment, the Japanese quantum ecosystem is growing fast.

This partnership demonstrates a mutual commitment from both IQM and TOYO to support the initiatives of the Japanese government in achieving its quantum strategy. Among the key goals, the government is aiming at 10 million domestic quantum users by 2030.

The partnership further underscores IQM’s commitment to advancing quantum technologies in the APAC region, complementing IQM’s current collaboration with Japan’s National Institute of Advanced Industrial Science and Technology (AIST).

IQM has delivered more on-premises quantum computers in the last 12 months than any other manufacturers to end-users in various countries, including South Korea, Germany, Italy, Finland, and Poland.

“Japan has become one of the major countries in quantum computing and our partnership with TOYO, a company with a proven track record of serving the Japanese industries with technological solutions, signals our strong commitment to providing our market-leading full stack quantum computers and advance the practical application of quantum computing across various industries,” said Mikko Välimäki, Co-CEO of IQM Quantum Computers.

“This partnership represents a significant milestone, highlighting the strong commitment from both companies and the close alignment between IQM's technological focus areas and TOYO’s business domains. By leveraging our collective strengths, we will accelerate the deployment of quantum computers at universities, research institutions, and companies across Japan. Together, we will also nurture the quantum specialists and drive the social implementation of quantum technologies in Japan,” said Toshiya Kohno, President and CEO of TOYO Corporation.

By combining IQM's quantum technology with its technology and expertise, TOYO is diversifying its business areas and plans to establish a specialised unit dedicated to quantum technology by the end of 2025.

The company aims to pioneer new fields of application for quantum computers and promote the creation of use cases and the development of new business models. Additionally, through providing education and research opportunities using actual quantum system and collaborating with related companies and organisations.

About IQM Quantum Computers:

IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centers, research labs, universities, and enterprises that have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea, and the United States.

About TOYO Corporation:

TOYO Corporation contributes to technological innovations as a leading provider of advanced measurement solutions. Through its variety of business segments including Sustainable Energy, Automobile Solutions, e-Mobility, ICT, Ocean Defense and Security, and Life Science, the company is focused on providing solutions to emerging markets such as clean energy and autonomous vehicle development. TOYO also makes significant R&D investments to develop in-house technologies and products, and its growth strategies include investing in new business, conducting M&A, and developing its market presence in global markets. By making available the most advanced market-based solutions, TOYO is at the forefront of helping to shape industries and communities that are safe, environmentally responsible, and sustainable.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250806016289/en/

Contacts

Media contact:
Email: press@meetiqm.com
Mobile: +358504790845
www.meetiqm.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meetiqm.com
%2F&esheet=54303857&newsitemid=20250806016289&lan=en-US&anchor=www.meetiqm.com&i
ndex=1&md5=a2e55f06a179c7511d65b7da1f03ca0b

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye